ZakerSchwabkeyMD

Oncology • Tampa, FL

Hematologic Oncology

Hematology and Medical Oncology Fellow

Join to view full profile

Dr. Schwabkey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Schwabkey's full profile

Already have an account?

Office
12902 USF Magnolia Drive
Tampa, FL 33612
Is this information wrong?

Education & Training

H. Lee Moffitt Cancer Center and Research InstituteFellowship, Hematology and Medical Oncology, 2021 - 2024
Albany Medical CenterResidency, Internal Medicine, 2018 - 2021
University of Texas M.D. Anderson Cancer CenterPost-Doctoral Fellowship, Research Fellowship, 2016 - 2018
Jordan University of Science and Technology FOMClass of 2014

Certifications & Licensure

UT State Medical License 2023 - 2026
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

11 citations
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment.
Zaker I Schwabkey, Diana H Wiesnoski, Chia-Chi Chang, Wen-Bin Tsai, Dung Pham, Saira S Ahmed, Tomo Hayase, Miriam R Ortega Turrubiates, Rawan K El-Himri, Christopher A...> ;Science Translational Medicine. 2022 Nov 16
AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia.
Ball S, Jain AG, Patel P, Wang C, Aguirre LE, Schwabkey ZI, Hussaini M, Chan O, Yun S, Kuykendall AT, Padron E, Sweet K, Lancet JE, Komrokji RS, Sallman DA> ;Clinical lymphoma, myeloma & leukemia.
AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia - Day 1 vs Day 1, 4 and 7 Regimen.
Jain A, Wang C, Ball S, Aguirre L, Schwabkey Z, Tobon K, Kuykendall A, Chan O, Padron E, Lancet J, Komrokji R, Sweet K, Sallman D> ;Clinical lymphoma, myeloma & leukemia.
MDS-408 Partial Splenic Embolization in Patients With Myelodysplastic Syndrome and Myelofibrosis.
Schwabkey Z, Ali NA, Gyano M, Kuykendall A, Kis B, Komrokji R> ;Clinical lymphoma, myeloma & leukemia.
MDS-504 Mutation Profiling and Characteristics of Hypoplastic MDS.
Azem A, Ali NA, Schwabkey Z, Chan O, Lancet J, Sweet K, Kuykendall A, Padron E, Sallman D, Komrokji R> ;Clinical lymphoma, myeloma & leukemia.
10 citations
Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation
Zaker Schwabkey, Robert R. Jenq> ;Annual Review of Medicine. 2020 Jan 27
5 citations
Impact of obesity on survival of patients with myelodysplastic syndromes.
Zaker I. Schwabkey, Najla Al Ali, David A. Sallman, Andrew T. Kuykendall, Chetasi Talati, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Rami S. Komrokji> ;Hematology. 2021 May 24
Congenital dysfibrinogenaemia presented with preterm premature rupture of the membranes and vaginal bleeding.
Zaker I Schwabkey, Farrell C Sheehan, Courtney M. Bellomo, Mihir Raval> ;BMJ Case Reports. 2020 Sep 1
Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype.
Zaker I. Schwabkey, Najla Al Ali, Onyee Chan, David A. Sallman, Eric Padron, Andrew T. Kuykendall, Chetasi Talati, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jan 1
36 citations
Clinical Evidence for the Microbiome in Inflammatory Diseases.
Ann E. Slingerland, Zaker Schwabkey, Diana H. Wiesnoski, Robert R. Jenq> ;Frontiers in Immunology. 2017 Apr 12
Join now to see all